128510-18-9

Upstream product

• 138573-41-8 2-[2-(2-Amino-6-trifluoromethyl-phenyl)-1-(4-methoxy-phenyl)-ethyl]-2-methyl-malonic acid dimethyl ester 
• 138573-29-2 2-[1-(4-Methoxy-phenyl)-2-(2-nitro-6-trifluoromethyl-phenyl)-ethyl]-2-methyl-malonic acid dimethyl ester 
• 111604-99-0 [1-(4-Methoxyphenyl)-2-[2-nitro-6-(trifluoromethyl)phenyl]ethyl]propanedioic acid,dimethyl ester 
• 111605-18-6 (3S,4S)-4-(4-Methoxy-phenyl)-3-methyl-2-oxo-6-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepine-3-carboxylic acid methyl ester 
• 7443-25-6 dimethyl 2-(4-methoxybenzylidene)malonate 
• 6656-49-1 2-methyl-1-nitro-3-(trifluoromethyl)benzene 

Downstream Products

• 138383-20-7 (3S,4S)-1-(2-Amino-1-methyl-ethyl)-4-(4-methoxy-phenyl)-3-methyl-6-trifluoromethyl-1,3,4,5-tetrahydro-benzo[b]azepin-2-one 

Relevant academic research and scientific papers

Benzazepinone calcium channel blockers. 4. Structure-activity overview and intracellular binding site

We have synthesized a series of benzazepinones (2) in order to determine the structure-activity relationships (SAR) for calcium channel blockers related to diltiazem. A prerequisite for calcium channel blocking activity in vitro and in vivo is the presenc